Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. euroxpand

EuroXpand SIGNED

EUROpean clinical validation of a new ex vivo eXpanded stem cell theraPy for cArdiac regeNeration after acute myocarDial infarction: EUROXPAND

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 EuroXpand project word cloud

Explore the words cloud of the EuroXpand project. It provides you a very rough idea of what is the project "EuroXpand" about.

total    ami    issue    clinical    euroxpand    stemxpand    decreasing    centres    eacute    cells    therapy    infarction    least    socio    2008    countries    function    billion    treatments    thanks    indicated    health    expectancy    burdensome    worldwide    2021    turnover    cancer    stem    innovative    patented    fail    83    outstanding    patients    post    business    hence    myocardial    surgical    discoveries    kit    leader    context    cardiac    position    professional    demonstrated    expansion    jobs    life    reference    industrialised    first    heart    successful    stempack    safety    combined    thousands    operative    reg    recovery    founded    founder    reinsertion    worked    creation    affordable    unlike    75    model    acute    treatment    millions    35    direct    assets    prevent    death    cell    global    euros    indirect    prevention    proof    2022    limiting    invasive    competitors    cellprothera    possession    outcomes    automate    pilot    public    pr    hf    profile    demonstration    nor    excellent    characterised    efficacy   

Project "EuroXpand" data sheet

The following table provides information about the project.

Coordinator		 CELLPROTHERA 

Organization address
address: 12 RUE DU PARC
city: MULHOUSE
postcode: 68100
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country France [FR]
 Total cost 5˙000˙000 €
 EC max contribution 5˙000˙000 € (100%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-2-2016-2017
 Funding Scheme SME-2
 Starting year 2018
 Duration (year-month-day) from 2018-05-01   to  2021-04-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    CELLPROTHERA FR (MULHOUSE) coordinator 5˙000˙000.00

Map

 Project objective

Heart failure (HF) after acute myocardial infarction (AMI) remains the first cause of death in developed countries, above cancer, with a life expectancy less than 5 years. With an overall cost of 83 billion euros per year worldwide , HF represents a global public-health issue. Treatments following AMI are still characterised by burdensome surgical procedures and post-operative treatments which both fail to prevent HF development. In this context, CellProthera, founded in 2008, developed an innovative technology based on the discoveries of its founder, Pr. Hénon, who has worked on stem cells for more than 35 years. Unlike its competitors, CellProthera has already demonstrated the efficacy and the safety of its cell therapy, thanks to a successful Proof of Concept study. The clinical outcomes indicated an excellent safety profile associated with an outstanding long-term recovery of the cardiac function, facilitating socio-professional reinsertion. The process used during the pilot phase could not be patented nor industrialised, limiting its availability to all patients. Hence, Cellprothera has developed a patented cell expansion automate StemXpand®, combined with StemPack® Kit creating an innovative business model, and a new cell therapy process less invasive, more affordable, and decreasing health costs related to HF in the order of 50 to 75%. With the efficacy demonstration of the new process through EuroXpand project, Cellprothera’s cell therapy could become the reference treatment to prevent HF after AMI. This way, CellProthera will be in possession of all the assets required to achieve a leader position in HF prevention, after AMI. Indeed, with a potential of millions patients / year worldwide, Cellprothera’s total turnover is expected to reach 1,9 billion euros in 2021, associated to the creation of at least 40 direct jobs by 2022 and several thousands of indirect jobs, particularly in Cell Therapy Centres.

 Deliverables

List of deliverables.
Communication material (brochures, web…) Documents, reports 2020-02-12 17:33:26
Press Release - Project kick-off Documents, reports 2020-02-12 17:33:28

Take a look to the deliverables list in detail:  detailed list of EuroXpand deliverables.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "EUROXPAND" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "EUROXPAND" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

INTE-AFRICA (2019)

Integrating and decentralising diabetes and hypertension services in Africa

Read More  

INADVANCE (2019)

Patient-centred pathways of early palliative care, supportive ecosystems and appraisal standard

Read More  

AutoCRAT (2020)

Automated Cellular Robot-Assisted Technologies for translation of discovery-led research in Osteoarthritis

Read More